trial summary · NCT07332507
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma
Trial record from the TrialBase DB dataset, status RECRUITING, condition Recurrent Plasmablastic Lymphoma, sponsored by National Cancer Institute (NCI). Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving teclistamab may be safe and tolerable in treating patients with recurrent or refractory plasmablastic lymphoma.
Source record: https://clinicaltrials.gov/study/NCT07332507
Facts
| registry id | NCT07332507 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Recurrent Plasmablastic Lymphoma |
| sponsor | National Cancer Institute (NCI) |
| sponsor class | NIH |
| enrollment | 30 |
| start date | 2027-03-26 |
| primary completion | 2027-12-31 |
| completion | 2027-12-31 |
| results posted | not reported |
Conditions
- Recurrent Plasmablastic Lymphoma
- Refractory Plasmablastic Lymphoma
Interventions
- Biospecimen Collection
- Computed Tomography
- Positron Emission Tomography
- Teclistamab
Countries
- United States
Intervention types: DRUG, PROCEDURE
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.